Nyxoah

NYXH

Market cap $155M

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 10, 2026 , 11:00 pm CET / 5:00 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 55,232,558 new shares in connection with its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. Share capital: EUR 7,073,687.00 Total number of securities carrying voting rights: 99,926,284 (all ordinary shares) Total number of voting rights (= denominator): 99,926,284 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued (on May 31, 2026): 3,322,832 (all granted subscription rights; this number excludes 462,677 subscription rights that were issued but not yet granted) Total number of convertible bonds: 225 convertible bonds with a nominal value of EUR 83,000 per bond Total number of voting rights that can be obtained in case of conversion of all 225 convertible bonds at the current (revised) conversion price of EUR 1.48 per share: 12,618,243 (this number does not take into account the conversion of interest) * * * Contact: Nyxoah John Landry, CFOIR@nyxoah.com Attachment 2026 06 10 - Press release - Number of shares (ENG)

$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch Mont-Saint-Guibert, Belgium – June 10, 2026, 10:30 pm CET / 04:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), has completed a $95 million equity financing and anticipates receipt of the $15 million second tranche of its European Investment Bank loan, which represents an aggregate of $110 million in new capital. This milestone marks a turning point for Nyxoah as the Company enters its next phase of U.S.-driven growth and long-term value creation.

REGULATED INFORMATION Nyxoah Announces Closing of Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 10, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 55,232,558 ordinary shares at an offering price of $1.72 (EUR 1.48) per share, before underwriting discounts and commissions. The total gross proceeds from the public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, is approximately $95.0 million (approximately EUR 81.9 million).

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 5, 2026, 5:25 pm CET / 11:25 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 55,232,558 of its ordinary shares at an offering price of $1.72 (EUR 1.48) per share, before underwriting discounts and commissions. All of the ordinary shares are being offered by Nyxoah and there are no selling shareholders participating in the offering.

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – June 4, 2026, 10:02 pm CET / 4:02 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. All of the ordinary shares are being offered by Nyxoah and there are no selling shareholders participating in the proposed offering.

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Enters New Chapter of Long Term Value Creation Commencement of process to transition to a U.S.-based CEO Transition to support further acceleration of commercial Genio launch in the United States Mont-Saint-Guibert, Belgium – June 4, 2026, 10:01 pm CET / 4:01 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the commencement of a leadership transition process in order to further accelerate the Company's U.S. commercial traction. Following seven successful years leading Nyxoah, Olivier Taelman, together with the Board of Directors, has decided that this is the right moment to transition leadership to a U.S.-based Chief Executive Officer as the Company enters its next phase of U.S.-driven growth and value creation.

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 20, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 1,031,323 new shares on May 20, 2026 in connection with the contribution in kind of a receivable held by the holder of the convertible bonds issued by the Company on December 18, 2025. For more information on this transaction, please refer to the special report of the board of directors dated May 19, 20261.

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum

Nyxoah SA (NYXH) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Nyxoah SA (NYXH) Q1 2026 Earnings Call Transcript